Survodutide

4 articles in this topic.

Complete Guides

Survodutide: The Dual GLP-1/Glucagon Liver Drug

Survodutide is a dual GLP-1/glucagon receptor agonist targeting liver fat in MASH. Phase 2 results, weight loss data, mechanism, and Phase 3 trial status.

17 min read|Mar 20, 2026

All Articles

Survodutide

Survodutide and MASH: Why This Drug Targets Liver Fat

Survodutide achieved 47-62% MASH resolution in its Phase 2 trial. How the GLP-1/glucagon agonist targets liver fat through glucagon receptor activation.

13 min read|Mar 25, 2026

Survodutide

Survodutide Clinical Trial Data

Survodutide, a GLP-1/glucagon dual agonist, achieved up to 19% weight loss and 62% MASH resolution in phase 2 trials. Full clinical data breakdown.

12 min read|Mar 25, 2026

Survodutide

How Survodutide Differs from Other Dual Agonists

Survodutide shares the GLP-1/glucagon mechanism with mazdutide but targets MASH with FDA Breakthrough status. How it compares to tirzepatide and retatrutide.

13 min read|Mar 22, 2026